Solid Biosciences (SLDB)
(Real Time Quote from BATS)
$6.01 USD
-0.04 (-0.66%)
Updated Oct 11, 2024 11:36 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Solid Biosciences Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 124 | 214 | 208 | 155 | 84 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 6 | 15 | 4 | 3 |
Total Current Assets | 130 | 220 | 223 | 159 | 86 |
Net Property & Equipment | 7 | 10 | 6 | 8 | 12 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 1 | 1 |
Total Assets | 165 | 260 | 232 | 171 | 103 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 3 | 4 | 3 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 1 | 0 | 0 | 0 |
Accrued Expenses | 10 | 17 | 10 | 9 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 8 | 10 | 0 |
Total Current Liabilities | 15 | 23 | 24 | 24 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 10 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 1 | 2 | 0 | 1 | 1 |
Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 38 | 49 | 24 | 39 | 23 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 785 | 774 | 685 | 537 | 396 |
Retained Earnings | -659 | -563 | -477 | -405 | -316 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 126 | 212 | 208 | 132 | 80 |
Total Liabilities & Shareholder's Equity | 165 | 260 | 232 | 171 | 103 |
Total Common Equity | 126 | 212 | 208 | 132 | 80 |
Shares Outstanding | 20.10 | 19.50 | 7.30 | 5.60 | 3.00 |
Book Value Per Share | 6.29 | 10.85 | 28.52 | 23.59 | 26.68 |
Fiscal Year End for Solid Biosciences Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 190 | 206 | 124 | 143 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 7 | 8 | 6 | 5 |
Total Current Assets | NA | 198 | 214 | 130 | 148 |
Net Property & Equipment | NA | 5 | 6 | 7 | 7 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 2 | 2 |
Total Assets | NA | 231 | 249 | 165 | 185 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 1 | 1 | 0 | 0 |
Accrued Expenses | NA | 10 | 10 | 10 | 11 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 15 | 14 | 15 | 16 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 1 | 1 | 1 | 1 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 38 | 38 | 38 | 40 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 901 | 894 | 785 | 783 |
Retained Earnings | NA | -708 | -683 | -659 | -638 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 193 | 211 | 126 | 144 |
Total Liabilities & Shareholder's Equity | NA | 231 | 249 | 165 | 185 |
Total Common Equity | 0 | 193 | 211 | 126 | 144 |
Shares Outstanding | 38.60 | 38.30 | 37.80 | 20.10 | 20.00 |
Book Value Per Share | 0.00 | 5.05 | 5.57 | 6.29 | 7.22 |